	22103682D
1	SENATE BILL NO. 542
2	Offered January 12, 2022
3	Prefiled January 12, 2022
4	A BILL to amend and reenact § 54.1-3408.3 of the Code of Virginia, relating to Board of Pharmacy;
5	written certification for the use of cannabis products.
6	
	Patron—Marsden
7	
8 9	Referred to Committee on Education and Health
10	Be it enacted by the General Assembly of Virginia:
11	1. That § 54.1-3408.3 of the Code of Virginia is amended and reenacted as follows:
12	§ 54.1-3408.3. Certification for use of cannabis oil for treatment.
13	A. As used in this section:
14	"Botanical cannabis" means cannabis that is composed wholly of usable cannabis from the same parts
15	of the same chemovar of cannabis plant.
16 17	"Cannabis oil" means any formulation of processed Cannabis plant extract, which may include oil
18	from industrial hemp extract acquired by a pharmaceutical processor pursuant to § 54.1-3442.6, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol (CBD) or
19	tetrahydrocannabinolic acid (THC-A) and no more than 10 milligrams of delta-9-tetrahydrocannabinol
20	per dose. "Cannabis oil" does not include industrial hemp, as defined in § 3.2-4112, that is grown, dealt,
21	or processed in compliance with state or federal law, unless it has been acquired and formulated with
$\overline{22}$	cannabis plant extract by a pharmaceutical processor.
23	"Cannabis product" means a product that is (i) produced by a pharmaceutical processor, registered
24	with the Board, and compliant with testing requirements and (ii) composed of cannabis oil or botanical
25	cannabis.
26	"Designated caregiver facility" means any hospice or hospice facility licensed pursuant to
27	§ 32.1-162.3, or home care organization as defined in § 32.1-162.7 that provides pharmaceutical services
28	or home health services, private provider licensed by the Department of Behavioral Health and
29	Developmental Services pursuant to Article 2 (§ 37.2-403 et seq.) of Chapter 4 of Title 37.2, assisted
30	living facility licensed pursuant to § 63.2-1701, or adult day care center licensed pursuant to
31	§ 63.2-1701.
32 33	"Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of Medicine, a physician assistant licensed by the Board of Medicine, or a nurse practitioner jointly licensed by the
33 34	Board of Medicine and the Board of Nursing.
35	"Registered agent" means an individual designated by a patient who has been issued a written
36	certification, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, designated
37	by such patient's parent or legal guardian, and registered with the Board pursuant to subsection G.
38	"Usable cannabis" means any cannabis plant material, including seeds, but not (i) resin that has been
39	extracted from any part of the cannabis plant, its seeds, or its resin; (ii) the mature stalks, fiber produced
40	from the stalks, or any other compound, manufacture, salt, or derivative, mixture, or preparation of the
41	mature stalks; or (iii) oil or cake made from the seeds of the plant.
42	B. A practitioner in the course of his professional practice may issue a written certification for the
43	use of cannabis products for treatment or to alleviate the symptoms of any diagnosed condition or
44	disease determined by the practitioner to benefit from such use. The practitioner shall use his
45	professional judgment to determine the manner and frequency of patient care and evaluation and may
46	employ the use of telemedicine, provided that the use of telemedicine includes the delivery of patient
47 48	care through real-time interactive audio-visual technology. If a practitioner determines it is consistent with the standard of care to dispense botanical cannabis to a minor, the written certification shall
40 49	specifically authorize such dispensing. If not specifically included on the initial written certification,
50	authorization for botanical cannabis may be communicated verbally or in writing to the pharmacist at
50 51	the time of dispensing.
52	C. The written certification shall be on a form provided by the Office of the Executive Secretary of
53	the Supreme Court developed in consultation with the Board of Medicine Board. Such written
54	certification shall contain the name, address, and telephone number of the practitioner, the name and
55	address of the patient issued the written certification, the date on which the written certification was
56	made, and the signature or authentic electronic signature of the practitioner. Such written certification
57	issued pursuant to subsection B shall expire no later than one year after its issuance unless the
58	practitioner provides in such written certification an earlier expiration.

SB542

D. No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for the issuance of a certification for the use of cannabis products for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B.
Nothing in this section shall preclude the Board of Medicine from sanctioning a practitioner for failing to properly evaluate or treat a patient's medical condition or otherwise violating the applicable standard of care for evaluating or treating medical conditions.

E. A practitioner who issues a written certification to a patient pursuant to this section shall register
with the Board and shall hold sufficient education and training to exercise appropriate professional
judgment in the certification of patients. The Board shall not limit the number of patients to whom a
practitioner may issue a written certification. The Board may report information to the applicable
licensing board on unusual patterns of certifications issued by a practitioner.

F. A patient who has been issued a written certification shall register with the Board or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, a patient's parent or legal guardian shall register and shall register such patient with the Board. No patient shall be required to physically present the written certification after the initial dispensing by any pharmaceutical processor or cannabis dispensing facility under each written certification, provided that the pharmaceutical processor or cannabis dispensing facility maintains an electronic copy of the written certification.

G. A patient, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian, may designate an individual to act as his registered agent for the purposes of receiving cannabis products pursuant to a valid written certification. Such designated individual shall register with the Board. The Board may set a limit on the number of patients for whom any individual is authorized to act as a registered agent.

H. Upon delivery of cannabis oil by a pharmaceutical processor or cannabis dispensing facility to a
designated caregiver facility, any employee or contractor of a designated caregiver facility, who is
licensed or registered by a health regulatory board and who is authorized to possess, distribute, or
administer medications, may accept delivery of the cannabis oil on behalf of a patient or resident for
subsequent delivery to the patient or resident and may assist in the administration of the cannabis oil to
the patient or resident as necessary.

I. The Board shall promulgate regulations to implement the registration process. Such regulations
shall include (i) a mechanism for sufficiently identifying the practitioner issuing the written certification,
the patient being treated by the practitioner, his registered agent, and, if such patient is a minor or an
incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian; (ii) a process for
ensuring that any changes in the information are reported in an appropriate timeframe; and (iii) a
prohibition for the patient to be issued a written certification by more than one practitioner during any
given time period.

94 J. Information obtained under the registration process shall be confidential and shall not be subject to 95 the disclosure provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.). However, 96 reasonable access to registry information shall be provided to (i) the Chairmen of the House Committee 97 for Courts of Justice and the Senate Committee on the Judiciary, (ii) state and federal agencies or local 98 law enforcement for the purpose of investigating or prosecuting a specific individual for a specific 99 violation of law, (iii) licensed practitioners or pharmacists, or their agents, for the purpose of providing patient care and drug therapy management and monitoring of drugs obtained by a registered patient, (iv) 100 101 a pharmaceutical processor or cannabis dispensing facility involved in the treatment of a registered patient, or (v) a registered patient, his registered agent, or, if such patient is a minor or an incapacitated 102 adult as defined in § 18.2-369, the patient's parent or legal guardian, but only with respect to 103 information related to such registered patient. 104